Aging Pet Population Is 'Solid Longer-Term Tailwind' For IDEXX Labs: Analyst
Posted
Vandana Singh (via Benzinga)
IDEXX Laboratories reports Q1 EPS of $2.81 (up 10% Y/Y), with sales reaching $964M (7% increase). Revenue growth driven by Companion Animal Group and Water segments. Operating margin at 31.0%. 2024 revenue forecasted at $3.895-$3.965 billion.
Latest Ratings for IDXX
DateFirmActionFromTo Feb 2022Atlantic EquitiesInitiates Coverage OnOverweight Nov 2021Morgan StanleyInitiates Coverage OnOverweight Aug 2021Credit SuisseMaintainsOutperform
View More Analyst Ratings for IDXX
View the Latest Analyst Ratings
read more
Analyst Color,
Briefs,
Earnings,
Expert Ideas,
IDXX,
News,
Stories That Matter,
why it's moving,
Guidance,
Health Care,
Top Stories,
Analyst Ratings,
Movers,
Trading Ideas,
General,
IDXX,
US45168D1046,
News,
Analyst Color,
Earnings,
Guidance,
Health Care,
Top Stories,
Analyst Ratings,
Movers,
Trading Ideas,
General,
Benzinga
